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Blendy, 2008; Laorden et al., 2002b; Núñez et al., 2007a) . Enhanced responsiveness of HPA axis after morphine withdrawal has been associated with activation of noradrenergic neurons in the nucleus of solitary tract (NTS-A 2 ) that project to the hypothalamic PVN (Laorden et al., 2000b; Laorden et al., 2002b) . Therefore, we have suggested that one of the neuronal mechanisms that underlie morphine withdrawal-induced activation of the HPA axis may be dependent on activation of noradrenergic pathways innervating the PVN (Núñez et al., 2007b) . However, the possible involvement of CRF1R in the interaction between morphine withdrawal and the noradrenergic system innervating the PVN has not been well documented.
There is strong neurochemical and electrophysiological evidence suggesting an interaction between CRF and catecholaminergic systems. We have previously shown that there is an increase in hnRNA CRF expression which parallels an enhancement in phosphorylation in NTS (activation) and enzymatic activity of tyrosine hydroxylase (TH) in the PVN during morphine withdrawal (Núñez et al., 2007b; Núñez et al., 2007a) . CRF-positive terminals have been detected in contact with TH immunoreactive neurons within the locus ceruleus (LC) (Sauvage and Steckler, 2001 ) and CRF has been demonstrated to increase the activity of noradrenergic neurons projecting to the prefrontal cortex (Lavicky and Dunn, 1993) . In addition, it has been demonstrated the presence of CRF1R in the catecholaminergic neurons of the LC, ventral tegmental area (VTA) and NTS (Van Pett et al., 2000; Sauvage and Steckler, 2001 ). However, direct evidence for the effects of CRF antagonists on morphine withdrawal-stimulated stress axis and brain stress system has been not well documented.

Materials and Methods
Animals. Male Sprague-Dawley rats Harlan, Barcelona, Spain) were housed four-to-five per cage (length, 45 cm; width, 24 cm; height, 20 cm) in a room with controlled temperature (22±2ºC) and humidity (50±10%), with free access to water and food. Animals were adapted to a standard 12-h lightdark cycle for 7 days before the beginning of the experiments. All surgical and experimental procedures were performed in accordance with the European Communities Council Directive of 24 November 1986 (86/609/EEC) and the local Committees for animal research (REGA ES300305440012).
Drug treatment and experimental procedure. Rats were made dependent on morphine by subcutaneously (sc) implantation of two 75 mg morphine pellets (provided by the Ministerio de Sanidad, Madrid, España) under light ether anaesthesia. This procedure has been shown to produce consistent plasma morphine concentration beginning a few hours after the implantation of the pellets and a full withdrawal syndrome after acute injection of opioid antagonists (Frenois et al., 2002) . Dependence on morphine is achieved 24 h after implantation of pellets and remained constant for 15 days (Gold et al., 1994) .
Control rats received placebo pellets containing the excipient without morphine.
Six days after the implantation of morphine or placebo pellets, precipitated withdrawal was induced by sc injection of naloxone (1 mg/kg; in a volume of 1 ml/kg body weight) or saline (controls; 1 ml/kg) and then were observed for behavioural signs of withdrawal. The incidence of irritability was scored for 10 min at 5 min intervals. In addition, body weight loss was determined as the difference between the weight determined immediately before saline or MOL 62463 naloxone injection and a second determination made 60 min later. These signs are reliable markers of opiate withdrawal in morphine-dependent rats. The weight gain of the rats was checked during treatment to ensure that the morphine was liberated correctly from the pellets because it is known that chronic morphine treatment induces a decrease in body weight gain due to lower caloric intake (Núñez et al., 2009 ).
In order to determine the effect of inhibiting CRF1R on the morphine withdrawal-induced activation of the axis and brain stress system, NA turnover in the PVN, c-Fos expression in NTS-A 2 , central amygdala (CeA) and PVN (magno and parvocellular parts) and plasma corticosterone and ACTH concentrations were determined in morphine dependent and control rats treated with the selective CRF1 receptor antagonists CP-154,526 (20 or 30 mg/kg ip) or antalarmin (20 mg/kg ip) 30 min before the administration of naloxone or saline.
Doses of CRF1R antagonists were selected based on existing literature and the anti-withdrawal effects of the antagonists that were observed in previous reports. CP-154,526 was dissolved in 10 % Tween-80 and given in a volume of 1 ml/kg body weight. Antalarmin was dissolved in Tween 80. Sixty min after saline or naloxone injection, rats were sacrificed (between 11:00 and 12:00 h to avoid circadian variations in plasma levels of the hormones), the brains were rapidly removed, fresh-frozen, and stored immediately at -80ºC until use for Western-blot analysis and NA turnover. A second set of animals from each treatment group was used for CRF1R/TH colocalization and for c-Fos immunohistochemistry. One set of each treatment group was randomly assigned for plasma ACTH and corticosterone determination.
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Radioimmunoassay. Plasma levels of corticosterone and ACTH were measured by commercially available kits for rats (   125   I-CORT and  125 I-hACTH RIA; MP Biomedicals, Orangeburg, NY). The sensitivity of the assay was 7.7 ng/ml for corticosterone and 5.7 pg/ml for ACTH.
Western blotting. Brainstem tissue corresponding to NTS-A 2 cell group was dissected between the AP, rostrally, to the pyramidal decussation caudally (plane of sections relative to bregma: -13.68 to -14.60). Samples were placed in homogenization buffer (Núñez et al., 2007b) and equal quantities of total protein (40 g) were separated by 10% SDS-PAGE and transferred to PVDF membranes, and Western analysis was performed with goat polyclonal anti-CRF1R antibody (against peptide mapping within an internal region of CRF1R; 1:200 dilution; sc-12381; Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Quantification of immunoreactivity was carried out by densitometry. The integrated optical density of the bands was normalized to the background values. Antibody was stripped from the blots by incubation with stripping buffer (glycine 25mM and SDS 1%, pH 2), for 1 h at 37º C. Blots were subsequently reblocked and probed with 1:1000 anti-beta actin (rabbit polyclonal antibody, Cell Signalling #4967) as loading control. Protein levels were corrected for individual -actin levels.
Immunohistochemistry. Animals were perfused transcardially and brains were processed for visualization of CRF1R and TH using previously published MOL 62463
techniques (Núñez et al., 2007b for each rat and for all treatment groups by an observer blinded to the treatment protocol. Images were captured by means of a DMLB microscopy (Leica, Madrid, Spain) connected to a video camera (Leica) and an image analysis computer (Q500MC; Leica). C-Fos positive cell nuclei were counted. The boundaries of the NTS, the BNST, the CeA, and the dorsal medial parvocellular (mpd), ventral medial parvocellular (mpv), dorsal parvocellular (dp) and lateral magnocellular (pm) subdivisions of the PVN were outlined and the number of positive profiles was recorded after thresholding the images to a common level.
Total counts of the different brain regions were taken bilaterally at regularly spaced intervals and expressed as mean ± SEM.
Colocalization of CRF1R immunoreactivity with TH-positive neurons.
Sections in the NTS-A 2 were collected from area postrema (AP) to obex, according to the map of (Paxinos and Watson, 2007) . Positive CRF1R immunoreactivity was detected using the same conventional light microscopy described above. CRF1R-positive TH cells were identified as cells with brown 
Results
TH immunoreactivity in the NTS-A 2 and co-localization of TH and CRF1R.
As previously shown (Núñez et al., 2007b; Núñez et al., 2009) , high densities of TH positive cell bodies and fibers were seen at the level of NTS, which corresponds to the acknowledged distribution of TH mRNA (Rusnak et al., 2001 ). TH neurons were very strongly and ubiquitously stained for CRF1R. In addition, a high number of TH-positive cells expressing CRF1R were found in the two treatment groups tested: control pellets plus vehicle plus naloxone and morphine plus vehicle plus naloxone. However, the high density of TH cell bodies and fibers prevented counting of TH-positive neurons and, therefore, did not allow any evaluation of the percentage of TH-positive neurons coexpressing CRF1R (Fig. 1A, B , B').
Influence of morphine withdrawal on CRF1R immunoreactivity in NTS as
determined by Western blot. Figure 1C shows that there was no significant modification of CRF1R immunoreactivity levels during morphine withdrawal compared with control group receiving naloxone and also compared with morphine plus saline-treated rats. No changes were observed in CRF1R levels in the NTS in control rats receiving naloxone compared with control pelletstreated group injected with saline.
Effects of CRF1R antagonists on naloxone-precipitated withdrawal signs
in morphine-dependent rats. Student t-test showed that chronic morphinetreated rats had significantly lower weight gain (4.62±1.60 g; t 97 =10.17; p <0.001; n=41) than placebo control group (24,0400±1.42 g; n=58). Fig. 2A shows that naloxone injection to morphine-dependent rats pretreated with This article has not been copyedited and formatted. The final version may differ from this version. vehicle produced a significant (p <0.001) increase in body weight loss ( Fig. 2A) compared with the control pellets-treated group also receiving naloxone and with morphine-treated rats given saline. However, administration of naloxone to the control rats resulted in no significant changes in body weight loss 1 h after drug injection, compared with control rats receiving saline.
A significant increase in body weight loss was seen in morphine- whereas plasma ACTH levels in morphine rats treated with saline or in placebo rats receiving saline or naloxone were not modified by CP-154,526.
Effects of CRF1R antagonists on naloxone-induced NA turnover in the hypothalamic PVN. Newman-Keuls post hoc test shows that naloxone injection to morphine-dependent rats pretreated with vehicle produced a significant increase in NA turnover (Fig. 3A) compared with the placebo-pelleted group also receiving naloxone (p <0.001) and with morphine-treated rats given saline (p <0.01). However, administration of naloxone to placebo-pelleted rats resulted in no significant changes in NA turnover 1 h after drug injection, compared with control rats receiving saline. As shown in Figure 3B (Figs. 4, 5) . In addition, c-Fos expression in placebo rats was significantly elevated over control levels at PVN in animals receiving CP-154,526 (Fig. 4B ).
This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
The principal findings of the present study are: (i): CRF1R is expressed in the NTS-A 2 cell group; (ii): CRF1R antagonists significantly decreased body weight loss and irritability during morphine withdrawal; (iii): pretreatment with CRF1R antagonists did not block either the increased NA turnover or corticosterone release, whereas plasma ACTH levels were significantly attenuated by CP-154,526; and (iv): brain stress system (which includes, among other nuclei, the NTS-A 2 , the CeA and the PVN) activation after naloxone injection to morphine-dependent rats was not attenuated by CRF1R
antagonists pretreatment.
Evidence for CRF1R mRNA within NTS has been demonstrated in the rat (Van Pett et al., 2000) . The present study extended these findings by demonstrating immunochemical evidence for CRF1R protein expression in rat NTS-A 2 catecholaminergic neurons innervating the PVN. Several studies have shown that increased CRF release contributes to the anxiety and aversive states produced by drug withdrawal (Zorrilla and Koob, 2004; Gallagher et al., 2008) , and recruitment of the CRF system has been hypothesized to be involved in drug dependence (Koob, 2008) . Accordingly, antagonism of CRF neurotransmission attenuated the anxiety-like and aversive effects of drug withdrawal (Stinus et al., 2005) . In addition, previous findings have shown anxiolitic-like action of CRF1R antagonists (Contarino and Papaleo, 2005) .
Consistent with these studies, we observed that both CP-156,526 and antalarmin suppressed the anxiety-like behaviour during morphine withdrawal.
This article has not been copyedited and formatted. The final version may differ from this version. (Lu et al., 2000b; Koob, 2008) .
NA has been implicated in addiction, in particular in opiate withdrawal (Maldonado, 1997; Smith and Aston-Jones, 2008) . Clinical findings and studies in animals have shown that systemic administration of adrenoceptor antagonists reduces the somatic signs of opiate withdrawal (Laorden et al., 2000b; AstonJones and Harris, 2004) . The present findings demonstrate that administration of naloxone to morphine dependent rats significantly elevated NA turnover in the PVN, which projects from NTS-A 2 . Previous reports have shown that activation of noradrenergic terminals innervating the PVN modulates the HPA axis activity in response to morphine withdrawal. Thus, naloxone-induced morphine withdrawal increases NA turnover and c-Fos expression in the PVN concomitantly with an increase in the activity of NTS-A 2 TH positive neurons (as reflected by c-Fos expression) (Laorden et al., 2002b; Laorden et al., 2002a; Smith and Aston-Jones, 2008) . These effects were dependent on adrenoceptor activation, which indicates that the hyperactivity of the HPA axis This article has not been copyedited and formatted. The final version may differ from this version. during morphine withdrawal is mediated via stimulatory noradrenergic pathways (Laorden et al., 2000b) . Additionally, we reported that morphine withdrawal is associated with an increase in TH enzymatic activity in the PVN as well as TH phosphorylation (activation) at Ser31 and TH mRNA expression in NTS-A 2 noradrenergic cell group (Núñez et al., 2009; Núñez et al., 2007b) , which occurred in parallel to increased hnRNA CRF and AVP expression in the PVN (Núñez et al., 2007a) . There are evidences supporting that CRF neurons in the PVN innervate noradrenergic brain stem nuclei (Gray and Magnuson, 1987) and it has been proposed the existence of a NA-CRF loop in which NA would stimulate the release of CRF in CeA, the PVN and the bed nucleus stria terminalis (BNST). CRF from these nuclei would induce the release of NA by the brain stem noradrenergic areas (Koob, 1999) . The results of the present study demonstrated that pretreatment with the selective CRF1R antagonists CP-154,526 or antalarmin, did not block the increased noradrenergic activity in the PVN during morphine withdrawal. These findings suggest that activation of CRF1R subtype is not responsible for the elevation of NA neurotransmission innervating the PVN. Our results are inconsistent with findings of previous studies in mice (Funada et al., 2001) , showing that the CRF1R antagonist response to drug withdrawal and stress (Deak et al., 1999) . Taken into account the above findings, it is possible that pituitary-adrenal response is not related with the behavioural signs of precipitated opiate withdrawal in rats.
It is well known that CRF receptors, in particular CRF1R subtype, are widely distributed in the brain, as well in the anterior pituitary gland. Mice and rats seem to show comparable distribution, while density of immunoreactivity differs in a structure-dependent manner (Van Pett et al., 2000) . This differential distribution of CRF1R and CRF2R implicates that these receptors exert different functions that are controlled by different mechanisms. According to the distribution of CRF receptors, the results of the present study would suggest that the effects of CRF1R antagonists were at anterior pituitary level (so attenuating ACTH release), but not at NTS, where robust hybridization signal for CRF2R mRNA has also been found (Van Pett et al., 2000) . Taken together, these findings would suggest that CRF2R subtype might mediate the activation of NA system innervating the PVN during morphine withdrawal.
According to previous data from our laboratory (Laorden et al., 2002a; Núñez et al., 2007a; Laorden et al., 2002c) , c-Fos expression was induced in several nuclei of the brain stress system (NTS, CeA, and PVN) 60 min after naloxone-induced morphine withdrawal. Activation of HPA axis during naloxone-precipitated morphine withdrawal involves transcriptional upregulation of CRF and AVP expression in the PVN (Núñez et al., 2007a) . We also have previously shown that increased c-Fos expression in the PVN during morphine withdrawal was abolished by adrenergic receptor antagonists, which
indicates that neuronal activation of PVN is depending on increased NA release (Laorden et al., 2002b) . In the present study, pretreatment with CP-154,526 did This article has not been copyedited and formatted. The final version may differ from this version. activation. Since all these structures also express CRF2R (Van Pett et al., 2000) , it is possible that morphine withdrawal may activate neurons in the brain stress system via CRF2R. In addition, high c-Fos expression was found in the PVN from placebo-pelleted rats receiving CP-154,526. A number of cellular and molecular mechanisms may be involved. One might include a compensatory agonist activation of the CRF2R subtype as a result of the blockade of the CRF1R.
In conclusion, the present study indicated that systemically bioavailable and selective CRF1R antagonists attenuated the irritability and weight loss signs of opiate withdrawal as well as ACTH hypersecretion. However, these antagonists had no detectable impact on NA turnover and c-Fos expression during naloxone-induced morphine withdrawal. These data suggest that CRF1R activation may not contribute to the increased brain stress system response in morphine-withdrawn rats. Future research is needed to determine the regions in which CRF1R signalling modulates ACTH release associated with opiate withdrawal and if the CRF2R subtype plays a role.
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